FTSE MIB
33.922,16 +40,66 (+0,12%) Dow Jones
38.018,31 +242,93 (+0,64%) Nasdaq
15.386,10 -215,39 (-1,38%) Nikkei 225
37.068,35 -1.011,35 (-2,66%) Petrolio
83,42 +0,69 (+0,83%) Bitcoin EUR
60.251,09 +773,84 (+1,30%)
Evelo Biosciences, Inc. (EVLO)
| Chiusura precedente | 0,0500 |
| Aperto | 0,0495 |
| Denaro | 0,0000 x 2900 |
| Lettera | 0,0000 x 1000 |
| Min-Max giorno | 0,0360 - 0,0495 |
| Intervallo di 52 settimane | 0,0280 - 13,9300 |
| Volume | |
| Media Volume | 38.433 |
| Capitalizzazione | 683.380 |
| Beta (5 anni mensile) | 2,03 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -15,6400 |
| Prossima data utili | 19 apr 2024 - 21 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 10,00 |
GlobeNewswireEvelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
– EDP2939 Phase 2 trial in moderate psoriasis fully enrolled with topline data expected early Q4 2023– Completed $25.5 Million Private Placement– Restructured and reduced secured debt with Horizon Technology Finance Corporation CAMBRIDGE, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), (“Evelo” or the “Company”) a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal ax
- GlobeNewswire
Evelo Biosciences Closes $25.5 Million Private Placement
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and decreases size of Board of Directors CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (the “Company” or “Evelo”), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announces that it closed the previously announced private plac
- GlobeNewswire
Evelo Biosciences Announces $25.5 Million Private Placement
CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered inflammation-resolving medicines acting on the small intestinal axis (SINTAX), today announced that it has entered into a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of its common stock (the “Shares”) at a purchase price of $2.31 per share, which would result in gross pro
